Vonoprazan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Vonoprazan is a potassium-competitive acid blocker used in the treatment of erosive diseases of the digestive tract, including reflux esophagitis and duodenal ulcers.

Generic Name

Vonoprazan

DrugBank Accession Number

DB11739

Background

Vonoprazan has been used in trials studying the treatment of Erosive Esophagitis.

Type

Small Molecule

Groups

Investigational

Structure

Similar Structures

Weight: Average: 345.39
Monoisotopic: 345.094726104
Chemical Formula: C₁₇H₁₆FN₃O₂S

Synonyms

Vonoprazan

Pharmacology

Indication

Vonoprazan is used in combination with amoxicillin and clarithromycin as co-packaged triple therapy or in combination with amoxicillin as co-packaged dual therapy to treat H. pylori infection in adults.²

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Alendronic acid	The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Vonoprazan.
Amphetamine	Vonoprazan can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Amprenavir	Vonoprazan can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Asunaprevir	Vonoprazan can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Atazanavir	Vonoprazan can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Belumosudil	The serum concentration of Belumosudil can be decreased when it is combined with Vonoprazan.
Bisacodyl	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Vonoprazan.
Bosutinib	Vonoprazan can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Budesonide	Vonoprazan can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Captopril	Vonoprazan can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Not Available

Products

: Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Chemical Identifiers

UNII: 1R5L3J156G
CAS number: 881681-00-1
InChI Key: BFDBKMOZYNOTPK-UHFFFAOYSA-N
InChI: InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
IUPAC Name: {[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine
SMILES: CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1

References

General References

FDA Thailand Product Information: Vocinti (vonoprazan fumarate) oral tablets [Link]
FDA Approved Drug Products: VOQUEZNA TRIPLE PAK (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets), co-packaged for oral use and VOQUEZNA DUAL PAK (vonoprazan tablets; amoxicillin capsules) co-packaged for oral use [Link]

External Links

PubChem Compound: 15981397
PubChem Substance: 347828097
ChemSpider: 13112797
BindingDB: 394392
RxNav: 2604577
ChEBI: 136048
ChEMBL: CHEMBL2079130
ZINC: ZINC000034842823
PDBe Ligand: HKT
Wikipedia: Vonoprazan

PDB Entries

5ylu

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Erosive Esophagitis	1
4	Completed	Treatment	Helicobacter Pylori Infection	1
4	Completed	Treatment	Reflux Esophagitis (RE)	1
4	Not Yet Recruiting	Prevention	Acute Coronary Syndrome (ACS) / Helicobacter Pylori Infection	1
4	Not Yet Recruiting	Treatment	Helicobacter Pylori Infection	1
4	Recruiting	Treatment	Eradication Therapy of Helicobacter Pylori	1
4	Recruiting	Treatment	Gastritis Chronic / Helicobacter Pylori Infection	1
4	Recruiting	Treatment	Gastro-esophageal Reflux Disease (GERD) / Gastroesophageal Reflux	1
4	Recruiting	Treatment	Helicobacter Pylori	1
4	Recruiting	Treatment	Helicobacter Pylori Infection	2

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral
Tablet, film coated	Oral	10 mg
Tablet, film coated	Oral	20 mg

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.049 mg/mL	ALOGPS
logP	1.78	ALOGPS
logP	2.03	ChemAxon
logS	-3.8	ALOGPS
pKa (Strongest Basic)	9.01	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	63.99 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	90.16 m³·mol^-1	ChemAxon
Polarizability	34.23 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Drug created at October 20, 2016 20:43 / Updated at July 02, 2022 12:49

Vonoprazan

Identification

Structure for Vonoprazan (DB11739)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra